ATE170077T1 - METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDE DERIVATIVES AND AN S-OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE INGREDIENT - Google Patents
METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDE DERIVATIVES AND AN S-OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE INGREDIENTInfo
- Publication number
- ATE170077T1 ATE170077T1 AT93907581T AT93907581T ATE170077T1 AT E170077 T1 ATE170077 T1 AT E170077T1 AT 93907581 T AT93907581 T AT 93907581T AT 93907581 T AT93907581 T AT 93907581T AT E170077 T1 ATE170077 T1 AT E170077T1
- Authority
- AT
- Austria
- Prior art keywords
- phase
- halomethylide
- derivatives
- active ingredient
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Abstract
The present invention relates to a method of treating a patient suffering from a neoplastic disease state comprising administering to said patient an effective antineoplastic amount of a 2'-halomethylidene derivative in conjunctive therapy with an effective antineoplastic amount of a S phase or M-phase specific agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86639992A | 1992-04-10 | 1992-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE170077T1 true ATE170077T1 (en) | 1998-09-15 |
Family
ID=25347526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93907581T ATE170077T1 (en) | 1992-04-10 | 1993-03-15 | METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDE DERIVATIVES AND AN S-OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE INGREDIENT |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040102461A1 (en) |
EP (1) | EP0664708B1 (en) |
JP (1) | JP3713668B2 (en) |
KR (1) | KR100258668B1 (en) |
AT (1) | ATE170077T1 (en) |
AU (1) | AU667527B2 (en) |
CA (1) | CA2117891C (en) |
DE (1) | DE69320646T2 (en) |
DK (1) | DK0664708T3 (en) |
ES (1) | ES2123642T3 (en) |
HU (1) | HU219476B (en) |
IL (1) | IL105329A (en) |
MX (1) | MX9302038A (en) |
NZ (1) | NZ251211A (en) |
TW (1) | TW362971B (en) |
WO (1) | WO1993020825A1 (en) |
ZA (1) | ZA932455B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001638A1 (en) * | 1994-07-11 | 1996-01-25 | Hoechst Marion Roussel, Inc. | Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy |
US5811408A (en) * | 1994-07-12 | 1998-09-22 | Yamasa Corporation | 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides |
ES2435722T3 (en) | 1997-09-04 | 2013-12-23 | Demerx, Inc. | Noribogaine in the treatment of pain and drug addiction |
US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
US6544962B1 (en) | 2000-11-02 | 2003-04-08 | Matrix Pharmaceutical, Inc. | Methods for treating cellular proliferative disorders |
JP2005522443A (en) * | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | Modified fluorinated nucleoside analogues |
AU2003280867A1 (en) * | 2002-11-04 | 2004-06-07 | Charite-Universitatsme Dizin Berlin | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
UA111065C2 (en) | 2010-07-23 | 2016-03-25 | Демеркс, Інк. | Noribogaine compositions |
EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
JP2015500833A (en) | 2011-12-09 | 2015-01-08 | デメレックス, インコーポレイテッド | Nolibogaine phosphate |
ES2702060T3 (en) | 2011-12-22 | 2019-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and their analogues |
US8877921B2 (en) | 2012-01-25 | 2014-11-04 | Demerx, Inc. | Synthetic voacangine |
US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
EP2934541A4 (en) | 2012-12-20 | 2016-08-03 | Demerx Inc | Substituted noribogaine |
CA2989550C (en) | 2014-06-18 | 2023-08-08 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
-
1993
- 1993-03-15 CA CA002117891A patent/CA2117891C/en not_active Expired - Fee Related
- 1993-03-15 AT AT93907581T patent/ATE170077T1/en not_active IP Right Cessation
- 1993-03-15 JP JP51832893A patent/JP3713668B2/en not_active Expired - Fee Related
- 1993-03-15 HU HU9402914A patent/HU219476B/en not_active IP Right Cessation
- 1993-03-15 NZ NZ251211A patent/NZ251211A/en not_active IP Right Cessation
- 1993-03-15 EP EP93907581A patent/EP0664708B1/en not_active Expired - Lifetime
- 1993-03-15 ES ES93907581T patent/ES2123642T3/en not_active Expired - Lifetime
- 1993-03-15 DE DE69320646T patent/DE69320646T2/en not_active Expired - Fee Related
- 1993-03-15 WO PCT/US1993/002490 patent/WO1993020825A1/en active IP Right Grant
- 1993-03-15 AU AU38131/93A patent/AU667527B2/en not_active Ceased
- 1993-03-15 DK DK93907581T patent/DK0664708T3/en active
- 1993-03-15 KR KR1019940703561A patent/KR100258668B1/en not_active IP Right Cessation
- 1993-04-05 ZA ZA932455A patent/ZA932455B/en unknown
- 1993-04-07 MX MX9302038A patent/MX9302038A/en not_active IP Right Cessation
- 1993-04-07 IL IL105329A patent/IL105329A/en not_active IP Right Cessation
- 1993-04-08 TW TW082102613A patent/TW362971B/en not_active IP Right Cessation
-
1998
- 1998-09-25 US US09/160,977 patent/US20040102461A1/en not_active Abandoned
-
2004
- 2004-09-17 US US10/943,429 patent/US20050032738A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2123642T3 (en) | 1999-01-16 |
HU219476B (en) | 2001-04-28 |
KR100258668B1 (en) | 2000-07-01 |
IL105329A0 (en) | 1993-08-18 |
DK0664708T3 (en) | 1998-11-02 |
HUT71224A (en) | 1995-11-28 |
JP3713668B2 (en) | 2005-11-09 |
EP0664708A4 (en) | 1995-04-24 |
AU3813193A (en) | 1993-11-18 |
CA2117891C (en) | 1998-07-07 |
IL105329A (en) | 1998-06-15 |
HU9402914D0 (en) | 1995-01-30 |
US20050032738A1 (en) | 2005-02-10 |
CA2117891A1 (en) | 1993-10-28 |
EP0664708A1 (en) | 1995-08-02 |
KR950700749A (en) | 1995-02-20 |
TW362971B (en) | 1999-07-01 |
MX9302038A (en) | 1993-10-01 |
JPH07505653A (en) | 1995-06-22 |
WO1993020825A1 (en) | 1993-10-28 |
US20040102461A1 (en) | 2004-05-27 |
AU667527B2 (en) | 1996-03-28 |
ZA932455B (en) | 1993-10-20 |
NZ251211A (en) | 1997-05-26 |
DE69320646D1 (en) | 1998-10-01 |
EP0664708B1 (en) | 1998-08-26 |
DE69320646T2 (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE170077T1 (en) | METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDE DERIVATIVES AND AN S-OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE INGREDIENT | |
ATE209908T1 (en) | RADICAL CAPTURER (ßSPIN TRAPSß) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS | |
DE69636343D1 (en) | USE OF GLU-TRP DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING VARIOUS VASCULAR REJECTION-ASSOCIATED DISEASES | |
ATE334668T1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES | |
DE69230112T2 (en) | ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE | |
DE69713526D1 (en) | SOLUBLE PACLITAXEL PRODRUGS | |
DE69322957T2 (en) | L - Deprenyl for the treatment of macular degeneration | |
DE69805973D1 (en) | TREATING HEART CRYSTAL DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM / CALMODULIN-DEPENDENT PROTEIN KINASE | |
BR9813318A (en) | Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient | |
ES2160643T3 (en) | COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF. | |
DE69429806D1 (en) | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING CANCER DISEASES AND METHODS FOR THEIR PRODUCTION | |
DE59002748D1 (en) | Process for the preparation of agents for the therapy of skin diseases. | |
RU94040886A (en) | Use of melatonine derivatives for sleep disturbance treatment, pharmaceutical composition | |
DE58904722D1 (en) | PREPARATION OF MEDICINAL PRODUCTS FROM ESTER DERIVATIVES OF HECOGENINE AND THE USE THEREOF FOR TREATING BENIGNER PROSTATE HYPERPLASIA. | |
ATE262330T1 (en) | USE OF A NITROXIDE OR ITS PRODRUG FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF CANCER | |
DE69218200T2 (en) | TREATMENT OF LIVER CANCER | |
DE69307702T2 (en) | USE OF (E) - 2 - (P -FLUOROPHENETHYL) - 3 - FLUOROALLYLAMINE FOR TREATING ALZHEIMER'S DISEASE | |
DE69733321D1 (en) | OLANZAPINE FOR THE TREATMENT OF DRUG ABUSE | |
RU94036344A (en) | Method for treating aids cases | |
RU94037731A (en) | Method for treating multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REN | Ceased due to non-payment of the annual fee |